Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002966620 | SCV003281945 | pathogenic | Combined malonic and methylmalonic acidemia | 2022-10-07 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Arg558 amino acid residue in ACSF3. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 21841779, 26827111; Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. This variant has not been reported in the literature in individuals affected with ACSF3-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Glu549*) in the ACSF3 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 28 amino acid(s) of the ACSF3 protein. |
Baylor Genetics | RCV002966620 | SCV005059929 | likely pathogenic | Combined malonic and methylmalonic acidemia | 2024-02-26 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002966620 | SCV005643697 | likely pathogenic | Combined malonic and methylmalonic acidemia | 2024-06-20 | criteria provided, single submitter | clinical testing |